Dyslipidemia shifts the tissue factor/tissue factor pathway inhibitor balance toward increased thrombogenicity in atherosclerotic plaques. Evidence for a corrective effect of statins

Atherosclerosis

Volumn 195, Issue 2, 2007, Pages

  Zawadzki, Christophe ^a,b   Susen, Sophie ^a,b   Richard, Florence ^c   Haulon, Stéphan ^b   Corseaux, Delphine ^a,b   Jeanpierre, Emmanuelle ^a,b   Vincentelli, André ^a,b   Lucas, Christian ^b   Torpier, Gérard ^c   Martin, Annie ^b   Van Belle, Eric ^a,b   Staels, Bart ^c   Jude, Brigitte ^a,b  

^a INSERM   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Atherosclerosis; Statin; Tissue factor; Tissue factor pathway inhibitor

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

AGED; ARTICLE; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; DEMOGRAPHY; DYSLIPIDEMIA; FEMALE; HISTOCHEMISTRY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; THROMBOGENICITY;

AGED; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; CAROTID ARTERY DISEASES; CASE-CONTROL STUDIES; COHORT STUDIES; DYSLIPIDEMIAS; ENDARTERECTOMY; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOHISTOCHEMISTRY; LIPOPROTEINS; MALE; THROMBOPLASTIN; THROMBOSIS;

EID: 36049030403     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.10.012     Document Type: Article

References (39)

1. Walldius G., Jungner I., Holme I., et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358 (2001) 2026-2033
2. Yusuf S., Hawken S., Ounpuu S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364 (2004) 937-952
3. Ardissino D., Merlini P.A., Bauer K.A., et al. Thrombogenic potential of human coronary atherosclerotic plaques. Blood 98 (2001) 2726-2729
4. Marmur J.D., Thiruvikraman S.V., Fyfe B.S., et al. Identification of active tissue factor in human coronary atheroma. Circulation 94 (1996) 1226-1232
5. Wilcox J.N., Smith K.M., Schwartz S.M., and Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 86 (1989) 2839-2843
6. Caplice N.M., Mueske C.S., Kleppe L.S., and Simari R.D. Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity. Circulation 98 (1998) 1051-1057
7. Drew A.F., Davenport P., Apostolopoulos J., and Tipping P.G. Tissue factor pathway inhibitor expression in atherosclerosis. Lab Invest 77 (1997) 291-298
8. Kaikita K., Takeya M., Ogawa H., et al. Co-localization of tissue factor and tissue factor pathway inhibitor in coronary atherosclerosis. J Pathol 188 (1999) 180-188
9. Crawley J., Lupu F., Westmuckett A.D., et al. Expression, localization, and activity of tissue factor pathway inhibitor in normal and atherosclerotic human vessels. Arterioscler Thromb Vasc Biol 20 (2000) 1362-1373
10. Ragni M., Golino P., Cirillo P., et al. Endogenous tissue factor pathway inhibitor modulates thrombus formation in an in vivo model of rabbit carotid artery stenosis and endothelial injury. Circulation 102 (2000) 113-117
11. St Pierre J., Yang L.Y., Tamirisa K., et al. Tissue factor pathway inhibitor attenuates procoagulant activity and upregulation of tissue factor at the site of balloon-induced arterial injury in pigs. Arterioscler Thromb Vasc Biol 19 (1999) 2263-2268
12. Badimon J.J., Lettino M., Toschi V., et al. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation 99 (1999) 1780-1787
13. Camera M., Toschi V., Comparato C., et al. Cholesterol-induced thrombogenicity of the vessel wall: inhibitory effect of fluvastatin. Thromb Haemost 87 (2002) 748-755
14. Jeanpierre E., Le Tourneau T., Six I., et al. Dietary lipid lowering modifies plaque phenotype in rabbit atheroma after angioplasty: a potential role of tissue factor. Circulation 108 (2003) 1740-1745
15. Aikawa M., Voglic S.J., Sugiyama S., et al. Dietary lipid lowering reduces tissue factor expression in rabbit atheroma. Circulation 100 (1999) 1215-1222
16. Lesnik P., Rouis M., Skarlatos S., Kruth H.S., and Chapman M.J. Uptake of exogenous free cholesterol induces upregulation of tissue factor expression in human monocyte-derived macrophages. Proc Natl Acad Sci USA 89 (1992) 10370-10374
17. Petit L., Lesnik P., Dachet C., Moreau M., and Chapman M.J. Tissue factor pathway inhibitor is expressed by human monocyte-derived macrophages: relationship to tissue factor induction by cholesterol and oxidized LDL. Arterioscler Thromb Vasc Biol 19 (1999) 309-315
18. Krysiak R., Okopien B., and Herman Z. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs 63 (2003) 1821-1854
19. Colli S., Eligini S., Lalli M., et al. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vasc Biol 17 (1997) 265-272
20. Aikawa M., Rabkin E., Sugiyama S., et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 103 (2001) 276-283
21. Hansen J.B., Huseby N.E., Sandset P.M., et al. Tissue-factor pathway inhibitor and lipoproteins. Evidence for association with and regulation by LDL in human plasma. Arterioscler Thromb 14 (1994) 223-229
22. MRC. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European carotid surgery trial (ECST). Lancet 1998;351:1379-87.
23. Stary H.C., Chandler A.B., Dinsmore R.E., et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 92 (1995) 1355-1374
24. Walsh J.D., and Geczy C.L. Discordant expression of tissue factor antigen and procoagulant activity on human monocytes activated with LPS and low dose cycloheximide. Thromb Haemost 66 (1991) 552-558
25. Zak B., Dickenman R.C., White E.G., Burnett H., and Cherney P.J. Rapid estimation of free and total cholesterol. Am J Clin Pathol 24 (1954) 1307-1315
26. Jude B., Susen S., Flan B., et al. Detection of monocyte tissue factor after endotoxin stimulation: comparison of one functional and three immunological methods. Thromb Res 79 (1995) 65-72
27. Carson S.D., Ross S.E., Bach R., and Guha A. An inhibitory monoclonal antibody against human tissue factor. Blood 70 (1987) 490-493
28. Mandal S.K., Iakhiaev A., Pendurthi U.R., and Rao L.V. Acute cholesterol depletion impairs functional expression of tissue factor in fibroblasts: modulation of tissue factor activity by membrane cholesterol. Blood 105 (2005) 153-160
29. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352 (2005) 29-38
30. Ridker P.M., Cannon C.P., Morrow D., et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005) 20-28
31. Cortellaro M., Cofrancesco E., Arbustini E., et al. Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: the ATROCAP study. Thromb Haemost 88 (2002) 41-47
32. Kang S., Wu Y., and Li X. Effects of statin therapy on the progression of carotid atherosclerosis: a systematic review and meta-analysis. Atherosclerosis 177 (2004) 433-442
33. Sato N., Kokame K., Miyata T., and Kato H. Lysophosphatidylcholine decreases the synthesis of tissue factor pathway inhibitor in human umbilical vein endothelial cells. Thromb Haemost 79 (1998) 217-221
34. Diamant M., Nieuwland R., Pablo R.F., et al. Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation 106 (2002) 2442-2447
35. Sambola A., Osende J., Hathcock J., et al. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation 107 (2003) 973-977
36. Zumbach M., Hofmann M., Borcea V., et al. Tissue factor antigen is elevated in patients with microvascular complications of diabetes mellitus. Exp Clin Endocrinol Diabetes 105 (1997) 206-212
37. Sommeijer D.W., Beganovic A., Schalkwijk C.G., et al. More fibrosis and thrombotic complications but similar expression patterns of markers for coagulation and inflammation in symptomatic plaques from DM2 patients. J Histochem Cytochem 52 (2004) 1141-1149
38. Migdalski A., Kotschy M., and Jawien A. Tissue factor, tissue factor pathway inhibitor and vascular endothelial growth factor-a in carotid atherosclerotic plaques. Eur J Vasc Endovasc Surg 30 (2005) 41-47
39. Matetzky S., Tani S., Kangavari S., et al. Smoking increases tissue factor expression in atherosclerotic plaques: implications for plaque thrombogenicity. Circulation 102 (2000) 602-604